Theratechnologies Shares Fall as FDA Continues to Review License Application for Tesamorelin
January 23 2024 - 9:16AM
Dow Jones News
By Adriano Marchese
Theratechnologies shares were sharply lower Tuesday morning
after the company said U.S. regulators will continue to review its
formulation to treat HIV-related weight imbalances.
At 9:37 a.m. ET, shares trading in Toronto were down over 13% at
2.15 Canadian dollars ($1.59).
The biopharmaceutical company said it has received a
correspondence from the U.S. Food and Drug Administration stating
that it will continue its review of Theratechnologies' supplemental
biologics license application for the F8 formulation of
tesamorelin.
Tesamorelin is a treatment for HIV-associated lipodystrophy,
syndromes that cause fat loss in some parts of the body while
gaining it in others.
The FDA told Theratechnologies that it is continuing its review
of the application beyond the Prescription Drug User Fee Act.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
January 23, 2024 10:01 ET (15:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Theratechnologies (TSX:TH)
Historical Stock Chart
From May 2024 to Jun 2024
Theratechnologies (TSX:TH)
Historical Stock Chart
From Jun 2023 to Jun 2024
